This result suggests that the inhibition of the PD-1/PD-L1 axis is more important than that of the TIGIT/CD155 axis in treating p-stage I adenocarcinoma, especially solid-predominant adenocarcinoma. Here, PDCD1 is linked to adenocarcinoma.